- Chimeric adenoviral vector Ad5/F35-mediated APE1 siRNA enhances sensitivity of human colorectal cancer cells to radiotherapy in vitro and in vivo
[作者：Xiang, DB; Chen, ZT; Wang, D; Li, MX; Xie, JY; Zhang, YS; Qing, Y; Li, ZP; Xie, J,期刊：Cancer gene therapy, 页码：625-635 , 文章类型： Article，,卷期：2008年15-10]
- Apurinic/apyrimidinic endonuclease (APE1), a bifunctional AP endonuclease/redox factor, is important in DNA repair and redox signaling, may be associated with radioresistance. Here we investigate whether targeted inhibit...
- Dual induction of PKR with E2F-1 and IFN-alpha to enhance gene therapy against hepatocellular carcinoma
[作者：Roh, V; Laemmle, A; Von Holzen, U; Stroka, D; Dufour, JF; Hunt, KK; Candinas, D; Vorburger, SA,期刊：Cancer gene therapy, 页码：636-644 , 文章类型： Article，,卷期：2008年15-10]
- Overexpression of the transcription factor E2F-1 induces apoptosis in tumor cells. This apoptotic effect is partly mediated through the induction of the double-stranded RNA-activated protein kinase (PKR). Here, we invest...
- Hypoxia-induced human endonuclease G expression suppresses tumor growth in a xenograft model
[作者：Winnard, PT; Botlagunta, M; Kluth, JB; Mukadam, S; Krishnamachary, B; Vesuna, F; Raman, V,期刊：Cancer gene therapy, 页码：645-654 , 文章类型： Article，,卷期：2008年15-10]
- We have developed a hypoxia-inducible gene therapy approach for the expression of the mature form of human endonuclease G to facilitate cell death in hypoxic regions of the tumor. The chimeric therapeutic gene is placed ...
- Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice
[作者：Sas, S; Chan, T; Sami, A; El-Gayed, A; Xiang, J,期刊：Cancer gene therapy, 页码：655-666 , 文章类型： Article，,卷期：2008年15-10]
- HER-2/neu transgene-modified dendritic cell (DC)-based vaccines are potent at eliciting HER-2/neu-specific antitumor immunity. In this study, we constructed a recombinant adenovirus (RGD)AdVneu with fiber gene modified b...
- Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells
[作者：Song, W; Dong, Z; Jin, T; Mantellini, MG; Nunez, G; Nor, JE,期刊：Cancer gene therapy, 页码：667-675 , 文章类型： Article，,卷期：2008年15-10]
- Antiangiogenic therapies have shown varying results partly because each tumor type secretes a distinct panel of angiogenic factors to sustain its own microvascular network. In addition, recent evidence demonstrated that ...
- Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck
[作者：Michaluart, P; Abdallah, KA; Lima, FD; Smith, R; Moyses, RA; Coelho, V; Victora, GD; Socorro-Silva, A; Volsi, EC; Zarate-Blades, CR; Ferraz, AR; Barreto, AK; Chammas, MC; Gomes, R; Gebrim, E; Arakawa-Sugueno, L; Fernandes, KP; Lotufo, PA; Cardoso, MR; Kalil, J; Silva, CL,期刊：Cancer gene therapy, 页码：676-684 , 文章类型： Article，,卷期：2008年15-10]
- Considering that mycobacterial heat-shock protein 65 (hsp65) gene transfer can elicit a profound antitumoral effect, this study aimed to establish the safety, maximum-tolerated dose (MTD) and preliminary efficacy of DNA-...
- Tissue-type plasminogen activator has antiangiogenic properties without effect on tumor growth in a rat C6 glioma model
[作者：Solly, F; Fish, R; Simard, B; Bolle, N; Kruithof, E; Polack, B; Pernod, G,期刊：Cancer gene therapy, 页码：685-692 , 文章类型： Article，,卷期：2008年15-10]
- Tissue-type plasminogen activator (tPA) plays a major role in the fibrinolytic system. According to several reports, tPA may also have antiangiogenic properties, especially in combination with a free sulfhydryl donor (FS...
|